Vincent Gagne

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.

Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.

Journal: Clinical pharmacology and therapeutics

Published: February 06, 2026

IL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT.

IL1B rs1143627 and IL17A rs8193036 in the risk of Acute Graft Versus Host Disease in pediatric HSCT.

Journal: Leukemia research

Published: November 03, 2025

Influence of xanthine oxidase and inosine monophosphate dehydrogenase polymorphisms on 6-mercaptopurine treatment response in pediatric acute lymphoblastic leukemia.

Influence of xanthine oxidase and inosine monophosphate dehydrogenase polymorphisms on 6-mercaptopurine treatment response in pediatric acute lymphoblastic leukemia.

Journal: Scientific reports

Published: September 05, 2025

Extrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia.

Extrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia.

Journal: Cancer research communications

Published: July 23, 2025

HLA-B15:01 and HLA-DRB107:01 as novel markers of acute GVHD in pediatric HSCT.

HLA-B15:01 and HLA-DRB107:01 as novel markers of acute GVHD in pediatric HSCT.

Journal: Bone marrow transplantation

Published: June 04, 2025

Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients.

Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients.

Journal: Pharmacogenetics and genomics

Published: April 29, 2024

IL16 and factor V gene variations are associated with asparaginase-related thrombosis in childhood acute lymphoblastic leukemia patients.

IL16 and factor V gene variations are associated with asparaginase-related thrombosis in childhood acute lymphoblastic leukemia patients.

Journal: Pharmacogenomics

Published: March 22, 2023

Pharmacogenetic Expression of CYP2C19 in a Pediatric Population.

Pharmacogenetic Expression of CYP2C19 in a Pediatric Population.

Journal: Journal of personalized medicine

Published: June 20, 2022

Characterization of the impact of the MYBBP1A gene and rs3809849 on asparaginase sensitivity and cellular functions.

Characterization of the impact of the MYBBP1A gene and rs3809849 on asparaginase sensitivity and cellular functions.

Journal: Pharmacogenomics

Published: April 29, 2022

Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.

Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.

Journal: Leukemia research

Published: May 10, 2021

HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium.

HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium.

Journal: Pharmacogenomics

Published: May 07, 2020

Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients.

Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients.

Journal: Pharmacogenomics

Published: November 06, 2019

Showing 1-12 of 24

Last Updated: 09/26/2026